<?xml version="1.0"?>

<document>
	<title>Negative effects of oral fatty acid supplementation on sweat
   chloride in cystic fibrosis.</title>

	<author>Lloyd-Still-J-D.</author>
	<author>Simon-S-H.</author>
	<author>Wessel-H-U.</author>
	<author>Gibson-L-E.</author>

	<source>Pediatrics. 1979 Jul. 64(1). P 50-2.</source>

	<abstract>Essential fatty acid supplementation with oral safflower oil (1
   gm/kg/day) to 11 cystic fibrosis patients (aged 6 months to 14 years)
   for one year produced no significant change in sweat chloride
   concentration (mEq/liter) or sweat rate (gm/min/m2), Addition of
   vitamin E (10 mg/kg/day) to the safflower oil had no effect on sweat
   chloride concentration or rate compared to placebo. No clinical
   improvement could be detected compared to a control group. These
   results do not support previous reports of the effects of fatty acid
   supplementation on sweat electrolyte concentrations in cystic
   fibrosis.</abstract>

	<majorsubject>CYSTIC-FIBROSIS: me</majorsubject>
	<majorsubject>OILS: pd</majorsubject>
	<majorsubject>SAFFLOWER-OIL: pd</majorsubject>
	<majorsubject>SODIUM-CHLORIDE: an</majorsubject>
	<majorsubject>SWEAT: an</majorsubject>

	<minorsubject>ADOLESCENCE</minorsubject>
	<minorsubject>CHILD</minorsubject>
	<minorsubject>CHILD-PRESCHOOL</minorsubject>
	<minorsubject>CYSTIC-FIBROSIS: bl, dt</minorsubject>
	<minorsubject>FEMALE</minorsubject>
	<minorsubject>HUMAN</minorsubject>
	<minorsubject>INFANT</minorsubject>
	<minorsubject>MALE</minorsubject>
	<minorsubject>PROSTAGLANDINS-E: bl</minorsubject>
	<minorsubject>PROSTAGLANDINS-F: bl</minorsubject>
	<minorsubject>SWEAT: de</minorsubject>

	<reference>001   ELLIOTT RB            ARCH DIS CHILD                  50    76 975</reference>
	<reference>002   ELLIOTT RB            PEDIATRICS                      57   474 976</reference>
	<reference>003   BEVERIDGE J           PEDIATRICS                      58   465 976</reference>
	<reference>004   ROSENLUND ML          PEDIATRICS                      59   428 977</reference>
	<reference>005   SHWACHMAN H           AM J DIS CHILD                  96     6 958</reference>
	<reference>006   GIBSON LE             PEDIATRICS                      23   545 959</reference>
	<reference>007   SCHWARTZ IL           J CLIN INVEST                   35   114 956</reference>
	<reference>008   SHWACHMAN H           MOD PROBL PEDIATR               10   158 967</reference>
	<reference>009   HOLMAN RT             PROC WEST HEM NUTR CONG 5TH              977</reference>
	<reference>010   HUBBARD VS            LANCET                           2  1302 977</reference>
	<reference>011   DUBOIS RS             GASTROENTEROLOGY                72  1052 977</reference>
	<reference>012   LEMEN RJ              AM REV RESPIR DIS              117   639 978</reference>
	<reference>013   CHASE HP              PEDIATR RES                     12   431 978</reference>
	<reference>014   HYMAN AL              AM REV RESPIR DIS              117   111 978</reference>

	<citation>1   ROGIERS V             PEDIATR RES                     14  1088 980</citation>
	<citation>2   LLOYDSTILL JD         AM J CLIN NUTR                  34     1 981</citation>
	<citation>3   HARPER TB             AM REV RESPIR DIS              126   540 982</citation>
	<citation>4   ROGIERS V             EUR J PEDIATR                  141    39 983</citation>
	<citation>5   ANON                  J AM COLL TOXICOL                4   171 985</citation>
	<citation>6   GIBSON RA             J PEDIATR GASTROENTEROL NUTR     5   408 986</citation>
	<citation>7   MISCHLER EH           PEDIATR RES                     20    36 986</citation>

</document>
